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1. Introduction  
Thiazolidinediones are class of compounds for 
treatment of type 2 diabetes mellitus. The efficacy of 
these drugs in decreasing plasma glucose level is well 
established. Rosiglitazone (RGN) a member of this class 
became available for clinical use in the United States in 
1999 (Parulkar et al., 2001). RGN requires insulin to be 
present for its action. RGN exerts its principal effects by 
increasing insulin sensitivity in peripheral tissue and also 
may lower glucose production by the liver. PPAR-γ 
agonist increase glucose transport into muscle and 
adipose tissue by enhancing the synthesis and 
translocation of specific forms of the glucose 
transporters. PPAR-γ agonist also can activate genes 
that regulate fatty acid metabolism in peripheral tissue 
(Havel, 2004; Davis, 2006). 
There has been increasing discussion about 
whether thiazolidinediones affect cardiac function, with 
evidence suggesting both negative and positive effects 
on myocardial performance.  Consequently, the 
practicing  cardiologist   is   often   faced   with  a  difficult 
 
  
decision about whether to initiate therapy with RGN 
because a large proportion of patients with diabetes 
often have coexisting ischemic and non-ischemic 
cardiomyopathy (Diep et al., 2002; Wang et al., 2003).  
The precise mechanism for the risk of heart failure 
associated with RGN is not known till now.  It is not 
known that whether the incidence of heart failure 
associated with RGN treatment is due to sodium 
retention and fluid accumulation or a direct cardiac 
depressant effect.   
Digoxin inhibits plasma membrane Na+, K+-ATPase, 
leading to a decrease in the net cellular uptake of K+ and 
a rise in intracellular Na+ concentration. Na+, K+-ATPase in 
the heart serves as a principal molecular receptor for the 
digitalis compounds (Demiryurek and Demiryurek, 2005). 
The rise in intracellular Na+ levels causes intracellular Ca2+ 
overload because of the reduction of Ca2+ efflux via the 
Na+-Ca2+ exchange system (Kalyoncu and Ozyavuz, 
1999). The increase in releasable Ca2+ from the 
sarcoplasmic reticulum is the biological substrate 
through which cardiac glycosides enhance myocardial 
contractility. In addition, co-administration of digoxin 
with RGN may be needed in some cases of diabetes 
This study was taken to investigate the effect of rosiglitazone (RGN) on the contractility of 
the isolated rat atrium as well as its possible inhibitory effect on positive inotropic effect of 
digoxin. RGN significantly increased the dose of digoxin required to produce cardiac arrest 
in anesthetized rats. RGN (10, 20, 40, 60, 80 & 100 µM) produced concentration dependant 
depressant effect on atrial contractility in both diabetic and non-diabetic animals with the 
depressant effect was more pronounced in diabetic rats than in non-diabetic ones. RGN 
also inhibited the positive inotropic effect of digoxin (0.1, 0.3 & 1µM) in isolated rat right 
atrium treated with 4 mg/kg orally daily for 21 days. Moreover, RGN also produced 
significant increase in serum K+ and decrease in Na+ levels in rats. These results indicate that 
RGN has a negative inotropic effect on the heart especially in diabetics and it inhibits the 
positive inotropic effect of digoxin. 
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mellitus with congestive heart failure. This concomitant 
administration did not affect steady-state 
pharmacokinetics of digoxin (DiCicco et al., 2000).  Thus, 
pharmacodynamic interactions may be expected by 
direct or indirect effect on the heart. Therefore, this 
study was undertaken to study the possible cardiac 
effect of RGN as well as pharmacodynamic interactions 
between RGN and digoxin. 
 
2. Materials and methods 
2.1. Chemicals and drugs 
 
Streptozotocin (STZ) and digoxin were purchased 
from Sigma Chemical Co. (St. Louis, MO, USA). RGN was 
obtained from Glaxo Smith Kline Pharmaceuticals 
(Worthing West Sussex. UK). Thiopental sodium was 
obtained from Egyptian Int. Pharmaceutical Industries 
Co. (EIPICO, 10th Ramadan City, Egypt). 
2.2. Animals 
 
Adult male Sprague Dawely rats weighing 180-250 g 
were used in this study (purchased from Urology and 
Nephrology Center, Mansoura University, Egypt). The 
experimental protocol conducted in the study complies 
with the ethical guidelines and the principals of care, use 
and handling of experimental animals adopted by "The 
research Ethics Committee", Faculty of Pharmacy, 
Mansoura University, Egypt. The adopted guidelines are 
in accordance with "Principles of Laboratory Animals 
Care" (NIH publication No. 85-23, revised 1985). The 
study protocol was approved by members of "The 
Research Ethics Committee" and by the head of 
Pharmacology and Toxicology department, Faculty of 
Pharmacy, Mansoura University, Egypt. 
2.3. Induction of diabetes 
 
Hyperglycemia was induced in rats by I.P. injection 
of STZ (60 mg/kg) (Mori et al., 2002), prepared in ice-cold 
0.1 M citrate buffer. Forty eight hours after STZ 
administration, diabetes was detected by urinary 
glucosuria using urine glucose strips.  One week after 
the onset of diabetes, blood samples were taken for 
determination of non-fasting (random) blood sugar.  
Animals with serum glucose level more than 350 mg/dl 
up to 520 mg/dl were used in this study (Khandoudi et 
al., 2002).  The day on which hyperglycemia had been 
confirmed was considered as day zero. 
 
2.4. In-vitro effect of RGN on the contractility of 
isolated right atrium of non-diabetic and diabetic 
rats 
 
The rats were anesthetized with ether. The heart 
was carefully removed and immediately placed in a Petri 
dish containing ice-cold oxygenated Kerbs-Henseleit 
Solution (KHS) of the following composition (mM):  NaCl 
118.4, KCl 4.7, CaCl2 2.5, NaHCO3 25, Mg SO4 1.2, KH2 PO4 
1.2 and glucose 11.7 (pH = 7.4).  After washing blood from 
the heart, the ventricular tissue, fat and connective 
tissue was trimmed off.  The atrium tissue was removed 
and transferred to another dish containing cold fresh 
KHS.  The right atrium was then carefully dissected and 
suspended vertically in a 20 ml tissue bath with KHS. One 
end of the atrium was attached to a tissue holder and 
the other end was mounted by silk thread and attached 
to isometric transducer (Harvard Apparatus LTD, MA, 
USA) that was connected to a two channel oscillograph 
(Haravard Apparatus).  The right atrium was allowed to 
beat spontaneously.  The tissue preparations were 
equilibrated at 37oC for 60 min in KHS aerated with a 
mixture of 95% O2 and 5% CO2.  During this period, the 
KHS in the tissue bath was replaced every 15 min.  
Resting tension of 1 g in the tissue preparation was 
maintained throughout the experiment. For tissues 
separated from non-diabetic and diabetic rats, after 
steady base-line recordings, a non-cumulative 
concentration-response curve was constructed for RGN 
at concentrations of (10, 20, 40, 60, 80& 100 M). The 
change in tension was measured and the % change in the 
contractility of the right atrium was calculated. 
The effects of addition of equivalent volume of the 
vehicle (0.025% ethanol as a final bath concentration) on 
the contractility of isolated right atria of non-diabetic 
and diabetic rats were observed in 6 preparations for 
each group. 
2.5. Effect of RGN incubation on digoxin-induced 
cardiotonic effect on isolated right atria of non-
diabetic and diabetic rats 
 
Tissue preparations (containing 8 preparations), 
prepared as previously mentioned, were isolated from 
non-diabetic and diabetic animals.  A cumulative 
concentrations response curve was constructed with 
regard to the inotropic effect of digoxin alone (0.1, 0.3& 
1 M) after preincubation with the vehicle (0.025% 
ethanol) for 10 min. Another groups of tissue 
preparations from non-diabetic and diabetic rats 
(comprising 8 preparations), after a steady base-line 
recording, were used to study the inotropic effect of 
digoxin in preparations preincubated with RGN (40 µM) 
for 10 min. 
 
2.6. Effect of daily treatment with RGN for 3 weeks on 
digoxin-induced cardiotonic effect on isolated 
right atria of diabetic rats 
 
One week after confirmation of diabetes, diabetic 
rats were randomly divided into 2 groups, in addition to 
control non-diabetic group:  
Group (1): Control non-diabetic rats received only the 
vehicle (0.5 ml/kg of 10% ethanol, I.P.) once 
daily for 3 weeks. 
Group (2):  Control diabetic rats received only the vehicle 
(0.5 ml/kg of 10% ethanol, I.P.) once daily for 
3 weeks. 
Group (3): Diabetic rats received RGN (4 mg/kg, I.P.) 
once daily for 3 weeks. 
On day 22, blood samples were withdrawn from the 
retro-orbital plexus under ether anesthesia and serum 
was separated for biochemical analysis after treatment. 
The right atrium was isolated from each group, as 
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previously mentioned. After a steady base-line 
recording, a cumulative concentrations response curve 
was constructed with regard to the inotropic effect of 
digoxin alone (0.1, 0.3& 1 M). 
2.7. Effect of acute treatment with RGN on digoxin 
induced cardiotoxicity in anesthetized rats 
 
          Rats were divided into 2 groups (8 animals each). 
Group (1) : Control rats received the vehicle (0,5 mL/kg 
10% alcohol, I.P.) 1 hr before infusion of 
digoxin. 
Group (2): Treated rats received RGN (4 mg/kg) by I.P. 
injection 1 hr before infusion of digoxin. 
After anesthesia with thiopental sodium (40 mg/kg, 
I.P.), the jugular vein was exposed and canulated for 
digoxin intravenous (I.V.) infusion at a flow rate of 0.25 
ml/min (25 g/min) for one min every 5 min interval and 
the electrocardiogram (ECG) was recorded at standard 
lead II limb leads using hypodermic needle electrodes 
and a single channel ECG (Fukuda Cardisuny model B-501 
III, Japan). The electrocardiograph was standardized 
before each tracing so a 1mV pulse produces a square 10-
mm high. The paper (chart) speed was 50 mm/sec.  The 
threshold dose of digoxin required to cause death from 
fetal ventricular fibrillation or from complete heart block 
was determined. 
2.8. Estimation of serum glucose, potassium and 
sodium levels 
 
Glucose, potassium and sodium were determined in 
rat serum according to manufacturer instructions 
(Biomerieux Company, France). 
 
 
3. Results 
3.1.   In-vitro effect of RGN on the contractility of 
isolated right atria of non-diabetic and diabetic 
rats 
 
As shown in fig. 1 & 2, the incubation of the right 
atria of non-diabetic rats with different concentrations 
of RGN (10, 20, 40 & 60 M) produced little non-
significant increase in  the contractility followed  by 
significant decrease in the contractility at higher 
concentrations of RGN  (80 M & 100 M) when 
compared with vehicle treated group. While incubation 
of the right atria of diabetic rats with different 
concentrations of RGN produced significant decrease in 
the contractility in all tested concentrations (10, 20, 40, 
60, 80 & 100 M) when compared with vehicle treated 
group. The vehicle (at final bath concentration of 0.025% 
ethanol) did not produce any significant effect on the 
contractility of the isolated right atria of non-diabetic 
and diabetic rats. 
 
3.2.  In-vitro effect of RGN on digoxin-induced increase 
in the contractility of isolated right atria of non-
diabetic rats 
 
As shown in fig. 3 & 4, the preincubation of isolated 
right   atria  of  non-diabetic rats with RGN (40 M) for 10  
 
 
Figure 1. In-vitro effect of RGN on the contractility of isolated right 
atria of non-diabetic and diabetic rats. Values represent the mean  
SEM of 8 preparations for RGN treated groups and 6 preparations for 
the vehicle treated group 
*Significantly different from non-diabetic rats when compared 
together using unpaired Student’s t-test (P <0.05).  
O Significantly different from the corresponding mean value of the 
vehicle (0.025% ethanol) when compared together using unpaired 
Student’s t-test (P <0.05) 
 
 
 
Figure 2. The contractility response induced by Rosiglitazone (RGN) 
(10, 20, 40, 60, 80 & 100 M) on isolated right atrium of A) non-diabetic 
rat, B) diabetic rat 
 
Figure 3. In-vitro effect if rosiglitazone (RGN) on digoxin iduced 
increase in the contractility of isolated right atria of non-diabetic rats. 
Values represent the mean ±SEM of 8 preparations.  
*Significatly different from that treated with vehicle when compared 
using unpaired Student’s t-test (P<0,05)   
                   Vehicle                      RGN (40 µM)   
 
min produced significant decrease in the cardiotonic 
effect induced by digoxin in all tested concentrations 
(0.1, 0.3 & 1 M) when compared with the corresponding 
effect produced with digoxin in atrium preincubated 
with vehicle (0.025% ethanol). 
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Figure 4. The contractility response induced by digoxin (0,1; 0,3; and 1 
µM) on right atrium isolated from non-diabetic rat A) incubated with 
vehicle, B) pre-incubated with 40 µM RGN for 10 min 
 
 
3.3.  Effect of digoxin treatment on the contractility of 
isolated right atria of non-diabetic and diabetic 
rats 
 
As shown in fig. 5 and 8, the increase in the 
contractility of the atria of the control diabetic rats 
induced by digoxin showed significant decrease when 
compared with the corresponding value of control non-
diabetic animals in all tested concentrations (0.1, 0.3, and 
1 µM) 
 
3.4.   In-vitro effect of RGN on digoxin-induced increase 
in the contactility of isolated right atria of diabetic 
rats 
 
As shown in fig. 6 and 8, the preincubation of 
diabetic rats right atria with RGN (40 M) for 10 min 
before digoxin treatment produced significant lowering 
effect in the contractility when compared with that 
produced by digoxin in atria preincubated with the 
vehicle for 10 min in all tested digoxin concentrations 
(0.1, 0.3 &1 M). 
 
3.5.  Effect if daily treatment for 3 weeks with RGN on 
digoxin-induced increase in the contractility of 
isolated right atria of diabetic rats 
As shown in fig. 7 and 8, the treatment of diabetic 
rats with RGN (4 mg/kg, I.P., once daily for 3 weeks) 
showed significant decrease in the inotropic effect 
produced by digoxin in all tested concentrations (0.1, 0.3 
& 1 M) when compared with that of control diabetic 
animals. 
 
3.6. Effect of treatment with RGN on digoxin induced 
cardiotoxicity in anesthetized rats 
As shown in fig. 9, the infusion of digoxin in control 
group (0.5 ml/kg 10% ethanol, I.P., 1 hr before digoxin 
infusion)   produced  gradual  decrease  in  heart  rate  till 
complete heart block and cardiac arrest with lethal dose 
of about (2.285 ± 0.126 mg/kg),   while infusion of digoxin 
 
 
Figure 5. Effect of digoxin treatment on the contractility of isolated 
right atria of non-diabetic and diabetic rats. Values represent the 
mean ± SEM of 6 preparations 
*Significatly different from non-diabetic rats when compared using 
unpaired Student’s t-test (P<0,05)   
                   Non-diabetic group                     diabetic group   
 
 
Figure 6. In-vitro effect of rosiglitazone (RGN) on digoxin-induced 
increase in the contractility of isolated right atria of diabetic rats. 
Values represent the mean ± SEM of 6 preparations 
*Significatly different from that treated with vehicle when compared 
using unpaired Student’s t-test (P<0,05)   
                   Vehicle                       RGN (40 µM) 
 
 
 
Figure 7. Effect of daily treatment for 3 weeks with RGN treatment on 
digoxin-induced increase in the contractility of isolated right atria of 
diabetic rats. Values represent the mean ± SEM of 6 preparations 
*Significatly different from control diabetic atria when compared 
using unpaired Student’s t-test (P<0,05)   
                   Non-diabetic group                       diabetic group   
 
in RGN treated group (4 mg/kg, I.P., 1 hr before digoxin 
infusion) produced a significant increase in the lethal 
dose of digoxin (4.09 ± 0.22 mg/kg) needed to induce 
cardiac arrest.   
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Figure 8. The contractility response induced by digoxin (0.1, 0.3, and 1 
M) on right atrium isolated from diabetic rat A) vehicle 
pretreatment, B) RGN pre-incubation with 40 M RGN for 10 min, C) 
treated with IGN (4mg/kg I.P., once daily for 3 weeks). 
 
 
Figure 9. Effect of treatment with rosiglitazone (RGN) on the lethal 
dose of digoxin. Values represent the mean ± SEM of 8 preparations. 
*Significantly different from control group received vehicle (0,5 
mL/kg 10% ethanol) before digoxin infusion when compared using 
unpaired Student’s t-test (P<0.05) 
                   Vehicle                      RGN ( 4 mg/Kg I.P.) 
 
 
 
3.7.  Effect of once daily treatment for 3 weeks with 
RGN on serum glucose level in diabetic rats 
 
As shown in fig. 10, mean serum glucose level in 
control diabetic group was significantly higher than its 
initial value and that of control non-diabetic animals. 
RGN treatment showed a significant decrease in serum 
glucose level when compared with control diabetic value 
and control non-diabetic value. 
 
Figure 10. Effect of once daily treatment for 3 weeks with 
rosiglitazone (RGN), losartan (Los) and their combination once daily 
for 3 weeks on serum potassium level in diabetic rats. Values 
represent the mean ± SEM of 6 rats.  
*$ significantly different from control non-diabetic and control 
diabetic rats respectively using unpaired Student’s t-test (P<0.05) 
0 signicantly different from its initial value using paired Student’s t-
test (P<0.05) 
δ significantly different from the corresponding mean value of 
losartan (2 mg/kg, orally) treated diabetic animal using unpaired 
Student’s t-test (P<0.05)  
                   before treatment                      after treatment 
 
 
3.8.  Effect of treatment with RGN once daily for 3 
weeks on serum potassium level in diabetic rats 
 
As shown in fig. 11, serum potassium level in control 
diabetic rats was significantly less than both its initial 
value and control non-diabetic animals, but it was not 
significantly different from control non-diabetic value. 
Treatment of diabetic rats with RGN showed significant 
increase in serum potassium level when compared with 
its initial, control diabetic and control non-diabetic 
values. 
 
Figure 11. Effect of treatment with rosiglitazone (RGN), losartan (Los) 
and their combination once daily for 3 weeks on serum potassium 
level in diabetic rats. Values represent the mean ± SEM of 6 rats.  
*$ significantly different from control non-diabetic and control 
diabetic rats respectively using unpaired Student’s t-test (P<0.05) 
0 signicantly different from its initial value using paired Student’s t-
test (P<0.05) 
µ δ significantly different from the corresponding mean value of RGN 
(4 mg/kg, I.P.) losartan (2 mg/kg, orally) treated diabetic animal using 
unpaired Student’s t-test (P<0.05)  
                   before treatment                      after treatment 
 
 
3.9.  Effect of daily treatment for 3 weeks with RGN on 
serum sodium level in diabetic rats 
As shown in fig. 12, mean serum sodium level in 
control diabetic group was significantly higher than its 
S.A. Said and M.A. Nader / J.Food Pharm.Sci (2013), 35-42                                                          39 
 
 
initial value and that of control non-diabetic animals. 
RGN treatment showed a significant decrease in serum 
sodium level when compared with control diabetic 
value, while it was not significantly different from 
control non-diabetic value. 
 
Figure 12. Effect of daily treatment for 3 weeks with rosiglitazone 
(RGN), losartan (Los) an their combination on serum sodium level in 
diabetic rats. Values represent the mean ± SEM of 6 rats.  
*$ significantly different from control non-diabetic and control 
diabetic rats respectively using unpaired Student’s t-test (P<0.05) 
0 signicantly different from its initial value using paired Student’s t-
test (P<0.05) 
µ  significantly different from the corresponding mean value of RGN 
(4 mg/kg, I.P.) treated diabetic animal using unpaired Student’s t-test 
(P<0.05)  
                   before treatment                      after treatment 
 
 
4. Discussion 
 
 In the present study, the significant stable 
moderate hyperglycemia was produced in rats using 
streptozotocin. Mild to moderate diabetes but not 
severe diabetes is required in this study because RGN (an 
insulin sensitizer) is active only if some insulin is still 
produced by the pancreatic β-cell (Malinowski and 
Bolestal, 2000). Treatment of diabetic rats with RGN 
produced significant decrease in serum glucose level. 
This observed lowering in serum glucose level indicated 
the insulin sensitizing effect of RGN which promotes 
insulin-dependent glucose uptake into target tissues 
such as liver, adipose tissue and skeletal muscle, and 
enhances insulin-mediated suppression of hepatic 
glucose production (Umrani et al., 2002; Wu et al., 2004). 
In non-diabetic rat atria, RGN produced little non 
significant increase in the contractility at low RGN 
concentrations (10, 20, 40& 60 µM), but at high 
concentrations (80 &100 µM) significant depression in 
the contractility was produced when compared with 
vehicle treated group. Similarly, it was reported that 
both troglitazone and RGN have positive inotropic effect 
but not pioglitazone in normal isolated perfused rat 
heart (Furuse et al., 2001). The little rise in the 
contractility was suggested to be due to Ca2+ sensitizing 
action of PPAR-γ agonists. RGN produced a 
concentration dependent reduction in the contractility 
of right atria of diabetic rats. This depressant effect may 
be attributed to any of the following actions of RGN: a- It 
was reported that PPAR-γ activation by RGN increased 
NO production which activate Maxi K+ channel (Kim and 
Cheon, 2006). The opening of Maxi-K+ channel lead to 
hyperpolarization of membrane potential and thus 
closing of voltage-dependent Ca2+ channels  responsible 
for Ca2+ influx (Knock et al., 1999 ; Eto et al., 2001). b- 
RGN inhibits (L-type) Ca2+ current this effect occurred 
over a higher concentration range (Knock et al., 1999). c- 
Augmentation of delayed rectifier K+ current causes 
dramatic shortening of action potential duration and 
hence to the negative inotropic response in atria (Ono, 
2003). RGN inhibit delayed rectifier potassium channels 
(Knock et al., 1999 ; Eto et al., 2001). 
Our data revealed that preincubation of non 
diabetic atrial preparation by RGN (40 µM) showed 
significant reduction in the atrial contractility induced by 
digoxin when compared with its corresponding vehicle. 
This inhibitory effect of RGN on digoxin-induced 
inotropic effect may be due to the effect of RGN on 
some ion channels (Knock et al., 1999; Eto et al., 2001; 
Kim and Cheon, 2006).    
The result showed that digoxin-induced positive 
inotropic action in atria of diabetic rats was significantly 
reduced when compared with atria from non-diabetic 
animals. These data was in agreement with (Ku and 
Sellers, 1982; Grassby and McNeil, 1988).  The low basal 
Na+, K+-ATPase activity and the reduced binding of 
cardiac glycosides to Na+, K+-ATPase can explain the 
diminished response to them in tissue removed from 
chronically diabetic rats (McCullough and McNeil, 1983; 
Grassby and McNeil, 1988). Also, the low thyroid status 
of diabetic animals may influence myocardial 
responsiveness to cardiac glycosides by reducing Na+, K+-
ATPase activity (Grassby and McNeil, 1988).   
In this study, the significant reduction in the atrial 
contractility induced by digoxin in diabetic rats right atria 
preincubation with RGN (40 µM) for 10 min or right 
atrium separated from diabetic rats treated with RGN (4 
mg/kg, I.P., daily for 3 weeks) comparing with the 
corresponding vehicle of each preparation (Knock et al., 
1999 ; Eto et al., 2001). The effects of RGN on certain ion 
channels (Knock et al., 1999; Eto et al., 2001) may affect 
electrolytes balance that reduces the digoxin toxicity 
(Sundar et al., 1983). Also RGN restored the activity of 
ATP-sensitive K+ channels reduced by high glucose 
(Kinoshita et al., 2008). Activation of ATP-sensitive K+ 
channels in the heart in-vitro produced a negative 
inotropic and chronotropic actions (Kocic and 
Korolkiewicz, 1998).   
 The effect of RGN on digoxin-induced 
cardiotoxicity in anesthetized rats showed significant 
increase in the lethal dose of digoxin needed to induce 
cardiac arrest when rats injected with RGN (4 mg/kg, I.P., 
1 hr before digoxin infusion). Since RGN does not alter 
the pharmacokinetics of digoxin (DiCicco et al., 2000) 
and this inhibition of action occurs also in-vitro (isolated 
atria), accordingly pharmacodynamic interactions are 
expected. The exact mechanism of this interaction is 
unknown, but it may be due to the following 
mechanisms: increase in serum potassium level 
(hyperkalemia). This increase in serum K+ level is 
accompanied with cardiac depressant effect (Glazier et 
al., 1984) and was reported to inhibit digoxin-induced 
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arrhythmia (Sundar et al., 1983; Finnegan et al., 1984). 
The effect of RGN on myocardial potassium channels 
may cause a prolongation of action potential duration 
(APD) and may explain to some extent the antagonism 
of arrhythmogenic action of digoxin. 
iabetic rats showed a significant decrease in serum 
potassium level and increase in serum sodium level when 
compared with the control non-diabetic value (Tsuchida 
et al., 2001).  Diabetic rats produced a significant 
decrease in serum potassium level and increase in serum 
sodium level in comparison with their initial value.  This 
may be explained by the duration of diabetes. Also, it 
was concluded that hypokalemia might induce tubulo-
interstitial injury that would result in alterations in local 
vasoactive mediators that would favor Na+ retention 
(Suga et al., 2001). It was reported that in hyperglycemia, 
glucose enters the cell, it takes potassium with it to form 
glycogen or animal starch as a result dangerous, 
potentially lethal, low serum potassium can result 
(Knochel, 1977). Our data showed that treatment with 
rosigliazone with  significant decrease in serum sodium 
level and significant increase in serum potassium level 
when compared with control diabetic value. It was 
concluded that the normalization of blood glucose level 
after RGN treatment is accompanied by the restoration 
of the ability of dopamine to significantly inhibit the 
activity of Na+, K+-ATPase in proximal tubules and 
normalization of the upregulation of D1-receptor that 
was affected by hyperglycemia (Tsuchida et al., 2001). It 
was demonstrated that chronic treatment of pre-
diabetic Zucker rats with common insulin sensitizing 
drug, RGN, will maintain blood pressure in the normal 
range, reduce hyperglycemia, albuminuria and increase 
natriuretic ability.  
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